How to Get Trulicity in Alaska: Prescriptions, Telehealth, and Pharmacy Access

What Is Trulicity and Why Do Alaska Patients Seek It?

Trulicity (dulaglutide) is a glucagon-like peptide-1 (GLP-1) receptor agonist manufactured by Eli Lilly and injected once weekly to manage blood glucose in adults with type 2 diabetes. The FDA first approved it in September 2014, and the agency later expanded the label in 2020 to include reducing major adverse cardiovascular events (MACE) in adults with type 2 diabetes who have established cardiovascular disease or multiple cardiovascular risk factors [1].

Alaska has one of the highest rates of diabetes-related complications among Indigenous populations in the United States. The CDC's 2023 National Diabetes Statistics Report found that American Indian and Alaska Native adults carry a disproportionate burden of type 2 diabetes compared with the general U.S. population [2]. That context matters for prescribers and patients in the state: effective glucose-lowering with demonstrated cardiovascular benefit is not a luxury but a genuine clinical need for a large segment of the population.

The landmark REWIND trial (N=9,901, median follow-up 5.4 years) published in The Lancet in 2019 showed that dulaglutide 1.5 mg once weekly reduced the composite MACE endpoint by 12% versus placebo (HR 0.88 to 95% CI 0.79, 0.99, P<0.026) in patients with type 2 diabetes [3]. Roughly 69% of REWIND participants had no prior cardiovascular event at baseline, making this the first GLP-1 receptor agonist trial to demonstrate MACE reduction in a predominantly primary-prevention population [3].

Patients across the state, particularly those in rural and remote communities served by small clinics or community health aides, often turn to telehealth to access a prescriber who can initiate or continue dulaglutide therapy. The sections below walk through every step of that process.

Alaska's Telehealth Rules for Prescribing Trulicity

Alaska permits telehealth prescribing of non-controlled medications, including dulaglutide, without a prior in-person visit, provided the prescriber establishes a valid patient-physician relationship through a synchronous audio-video encounter. Alaska Statute AS 08.64.364 governs telehealth practice for physicians, and the Alaska State Medical Board has aligned its standards of care with in-person requirements [4].

Nurse practitioners (NPs) and physician assistants (PAs) licensed in Alaska may also prescribe dulaglutide. Alaska NPs practice under a collaborative agreement framework, though agreement requirements have been progressively reduced for experienced NPs in underserved areas. Alaska PAs require a written practice agreement with a supervising physician.

For telehealth visits specifically:

• The platform must use real-time, two-way audio and video. Asynchronous store-and-forward encounters alone are insufficient for an initial Trulicity prescription under Alaska Medical Board guidance.
• The prescriber must document a full medication history, allergy review, and contraindication screen (personal or family history of medullary thyroid carcinoma, MEN 2 syndrome) as required by the Trulicity FDA label [1].
• After the visit, the electronic prescription is transmitted directly to a pharmacy the patient designates, including mail-order pharmacies that ship to Alaska.

The American Diabetes Association's 2024 Standards of Care in Diabetes recommends GLP-1 receptor agonists as preferred add-on therapy after metformin in patients with established atherosclerotic cardiovascular disease, heart failure, or chronic kidney disease, regardless of HbA1c [5]. That guideline gives telehealth prescribers clear clinical grounding for initiating dulaglutide without requiring the patient to travel hundreds of miles to a specialist.

Labs Required Before Starting Trulicity in Alaska

A prescriber will typically order baseline labs before writing the first Trulicity prescription. Most telehealth platforms that operate in Alaska require these results within 90 days of the visit.

The standard panel includes:

• HbA1c. Confirms the type 2 diabetes diagnosis and establishes a baseline. The ADA defines diabetes as HbA1c 6.5% or higher on two separate tests [5].
• Comprehensive metabolic panel (CMP). Screens for hepatic and renal function. Dulaglutide does not require dose adjustment for renal impairment, but eGFR below 15 mL/min/1.73m2 is associated with higher GI adverse event risk [1].
• Lipid panel. Required by most payers for prior authorization and clinically relevant because patients initiating a GLP-1 agonist often have concurrent dyslipidemia.
• CBC. Not mandated by the FDA label but requested by many commercial insurers in Alaska as part of the prior authorization packet.
• TSH. Ordered if the patient has thyroid symptoms or family history of thyroid cancer, given the class warning around C-cell tumors seen in rodent studies [1].

Patients in rural Alaska can often complete labs at their nearest Alaska Native Tribal Health Consortium (ANTHC) clinic or through a mobile phlebotomy service. Results can then be uploaded to the telehealth platform's patient portal before the prescriber visit, reducing the number of separate appointments needed.

The Endocrine Society's 2022 Clinical Practice Guideline on Pharmacological Management of Type 2 Diabetes recommends establishing baseline renal and hepatic function before initiating any GLP-1 receptor agonist [6].

How to Get a Trulicity Prescription Step by Step

Getting a Trulicity prescription in Alaska follows a predictable sequence whether the patient works with an in-person provider or a telehealth platform.

Step 1: Complete baseline labs. Order or upload HbA1c, CMP, lipid panel, and CBC. Most results return within 24 to 72 hours through a commercial lab draw.

Step 2: Schedule a prescriber visit. Book with a licensed Alaska MD, DO, NP, or PA, either locally or via a telehealth service. The visit typically runs 20 to 30 minutes and covers diabetes history, current medications, contraindications, and injection training.

Step 3: Confirm no contraindications. Dulaglutide is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or MEN 2, and in patients with a prior serious hypersensitivity reaction to dulaglutide [1]. Pancreatitis history is a relative contraindication requiring careful risk-benefit discussion.

Step 4: Receive the electronic prescription. The prescriber sends the Rx to the pharmacy of the patient's choice. Patients in Fairbanks, Anchorage, or Juneau can fill at a local retail pharmacy. Patients in villages or remote areas typically designate a mail-order pharmacy.

Step 5: Manage prior authorization if using commercial insurance. Most Alaska commercial plans require PA for Trulicity. Documentation typically includes the HbA1c result, evidence of metformin trial (unless contraindicated), and the prescriber's clinical rationale. Processing takes 3 to 14 business days depending on the payer.

Step 6: First injection and follow-up. The starting dose is 0.75 mg SC once weekly for 4 weeks, then titration to 1.5 mg. A follow-up visit at 8 to 12 weeks assesses tolerability and HbA1c response [1].

Prior Authorization Requirements in Alaska

Prior authorization (PA) for Trulicity is required by virtually every commercial insurer operating in Alaska, including Premera Blue Cross, Moda Health, and most employer-sponsored plans. Alaska Medicaid does not cover Trulicity for type 2 diabetes, so Medicaid patients will not face a PA process but will need to explore alternative payment routes discussed below.

A typical commercial PA packet for dulaglutide in Alaska requires:

1. Confirmed type 2 diabetes diagnosis with ICD-10 code E11.x and a recent HbA1c value.
2. Evidence of metformin trial or documented contraindication. Most payers want at least 90 days of metformin at an adequate dose (1 to 000 mg twice daily) before approving a GLP-1 agonist as add-on therapy.
3. Prescriber attestation of cardiovascular risk factors or established ASCVD. Given the REWIND trial data and the FDA label's cardiovascular indication, payers increasingly accept cardiovascular risk as a standalone justification [3].
4. Step-therapy failure documentation. Some Alaska plans require a sulfonylurea or SGLT-2 inhibitor trial before approving a GLP-1 agonist, unless the patient has contraindications.

The American Association of Clinical Endocrinologists (AACE) 2023 Comprehensive Diabetes Management Algorithm states that GLP-1 receptor agonists with proven cardiovascular benefit should be preferred over agents without that evidence in patients with ASCVD or high cardiovascular risk, regardless of HbA1c level [7]. Citing this guideline directly in a PA appeal letter substantially increases approval rates when a payer initially denies on the grounds that HbA1c is not above a specified threshold.

If a PA is denied, the prescriber can file a peer-to-peer review request within 30 days. Alaska state law (AS 21.07.250) requires insurers to provide a peer-to-peer review process for prior authorization denials, and the clinical evidence base for dulaglutide in high-cardiovascular-risk patients is strong enough that many denials are overturned at this stage [8].

Pharmacy Options and Shipping to Alaska

Alaska residents have several pharmacy options for filling a Trulicity prescription. Dulaglutide requires refrigeration (2°C to 8°C), so cold-chain shipping is necessary for mail-order deliveries [1].

Retail pharmacies in Alaska. Major chains including Walmart Pharmacy and Fred Meyer Pharmacy operate in Anchorage and Fairbanks. Independent pharmacies in Juneau and Sitka also stock Trulicity, though smaller communities may need to special-order it with 5 to 7 business days lead time.

Mail-order pharmacies. CVS Caremark, Express Scripts, and Optum Rx all ship to Alaska addresses with validated cold-chain packaging. Standard delivery to Anchorage takes 2 to 4 business days; delivery to remote zip codes via bush mail can take 5 to 10 business days. Patients should confirm the pharmacy's cold-chain certification before the first shipment.

503A compounding pharmacies. Alaska permits 503A compounding pharmacies to compound medications for individual patients with a valid prescription. Compounded dulaglutide is not FDA-approved and is not bioequivalent-certified against Trulicity. The FDA has not placed dulaglutide on the 503A bulk drug substances list, which significantly limits the legal basis for compounding it [9]. Patients considering this route should confirm with their prescriber and the pharmacy that the compound is prepared under a valid patient-specific prescription and that the pharmacy holds a current Alaska Board of Pharmacy license.

The FDA's guidance on 503A compounding pharmacies clarifies that bulk drug substances used in compounding must appear on an FDA-approved list or be subject to a clinical need determination [9]. Patients and prescribers in Alaska should request written documentation of the pharmacy's legal basis for compounding dulaglutide before proceeding.

Cost and Coverage Without Alaska Medicaid

Alaska Medicaid does not cover Trulicity for the type 2 diabetes indication as of the date this article was reviewed. That is a significant access barrier given that Medicaid covers approximately 25% of Alaska residents, including a substantial proportion of Alaska Native and American Indian individuals who carry elevated diabetes risk [10].

Patients without coverage have several options:

Eli Lilly's Trulicity Savings Card. Commercially insured patients who are not enrolled in a federal or state government program may pay as little as $25 per month through Lilly's savings program. This is not available to Medicaid or Medicare beneficiaries.

Lilly Cares Foundation. Eli Lilly's patient assistance program provides Trulicity at no cost to qualifying uninsured or underinsured patients meeting income eligibility thresholds (generally at or below 400% of the federal poverty level).

Medicare Part D. Trulicity is covered under most Medicare Part D plans, though formulary placement and cost-sharing vary. The Inflation Reduction Act's $2,000 annual out-of-pocket cap for Part D beneficiaries took effect in 2025, reducing the financial burden for Medicare patients using branded GLP-1 agents.

GoodRx and discount programs. The cash price for a four-pen (one-month) supply of Trulicity 1.5 mg in Anchorage runs approximately $900 to $1,000 before discounts. GoodRx coupons can reduce this to $700 to $850 at participating pharmacies, though these prices fluctuate.

A 2022 analysis published in JAMA Internal Medicine found that list prices for GLP-1 receptor agonists in the United States increased substantially between 2010 and 2021, with dulaglutide among the drugs showing the steepest net price increases after rebates [11].

Transferring an Existing Trulicity Prescription to Alaska

Patients relocating to Alaska who already have a Trulicity prescription from another state face a straightforward but time-sensitive process.

A prescription written by an out-of-state prescriber is not valid in Alaska unless that prescriber holds an active Alaska license or the prescription is transferred to an Alaska-licensed provider. The Alaska State Medical Board does not offer a temporary reciprocity license for visiting patients.

The practical steps:

1. Request a transfer to an Alaska pharmacy. The original pharmacy contacts a licensed Alaska retail or mail-order pharmacy directly. The Alaska pharmacy can fill remaining refills on the transferred prescription if the prescribing provider holds a valid DEA registration (or Alaska license for non-controlled drugs).
2. Establish care with an Alaska-licensed prescriber. Schedule a telehealth or in-person visit within 60 to 90 days of relocation to ensure continuity. The new prescriber will write a new prescription under their Alaska license.
3. Update insurance. If changing employers or insurance plans upon relocation, the prior authorization process will need to restart with the new insurer.

The National Council for Prescription Drug Programs (NCPDP) standards require pharmacies to verify prescriber DEA and state license numbers at the point of dispensing, so an out-of-state-only license will flag at the pharmacy level and trigger the need for an Alaska-licensed provider [12].

Cardiovascular and Glycemic Evidence Supporting Trulicity

Prescribers in Alaska operate under the same evidence base as their counterparts nationwide, and that evidence base for dulaglutide is substantial.

The REWIND trial enrolled 9,901 adults across 24 countries with a mean age of 66.2 years, mean HbA1c of 7.3%, and mean diabetes duration of 10.5 years. After a median follow-up of 5.4 years, dulaglutide 1.5 mg once weekly reduced the composite MACE endpoint (cardiovascular death, non-fatal MI, non-fatal stroke) by 12% versus placebo (HR 0.88 to 95% CI 0.79, 0.99, P<0.026) [3]. Stroke reduction was the primary driver (HR 0.76 to 95% CI 0.61, 0.95), a finding particularly relevant for Alaska Native patients who have elevated stroke risk [3].

A secondary analysis of REWIND published in The Lancet Diabetes and Endocrinology found that dulaglutide also reduced the composite kidney outcome (new macroalbuminuria, sustained 40% eGFR decline, or renal replacement therapy) by 15% (HR 0.85 to 95% CI 0.77, 0.93, P<0.0004) [13].

For glycemic efficacy, a 2014 phase 3 trial (AWARD-5, N=1,098) published in Diabetes Care showed dulaglutide 1.5 mg reduced HbA1c by 1.10 percentage points versus sitagliptin's 0.39 percentage points at 52 weeks (P<0.001) [14]. The FDA label notes that dulaglutide is not recommended as first-line therapy for patients who can be managed with diet and exercise alone or with a single oral agent [1].

The 2024 ADA Standards of Care recommend that clinicians select a GLP-1 receptor agonist with proven cardiovascular benefit (a category that includes dulaglutide based on REWIND) for patients with type 2 diabetes and established ASCVD, high cardiovascular risk, heart failure, or diabetic kidney disease, independent of baseline HbA1c and independent of whether additional glucose lowering is needed [5].

Dosing, Administration, and Storage in Alaska's Climate

Dulaglutide is supplied as a single-dose auto-injector pen containing 0.5 mL of solution. The pen does not require reconstitution or priming [1].

Approved dosing schedule:

• Week 1 to 4: 0.75 mg SC once weekly
• Week 5 onward: 1.5 mg SC once weekly (standard maintenance)
• Optional titration to 3.0 mg at week 12 and 4.5 mg at week 24 if additional glycemic control is needed

Injections are given in the abdomen, upper arm, or thigh. Patients should rotate sites weekly. Dulaglutide can be administered without regard to meals, which simplifies adherence for patients with variable schedules common in Alaska's subsistence and commercial fishing communities.

Storage considerations for Alaska:

• Refrigerate at 36°F to 46°F (2°C to 8°C). Do not freeze.
• If refrigeration is unavailable, the pen may be stored at room temperature up to 86°F (30°C) for up to 14 days [1].
• In remote Alaska, where power outages are more frequent, patients should have a backup plan such as an insulated cooler with ice packs for short-term storage.
• Pens exposed to temperatures above 86°F for more than 14 days or that have been frozen should be discarded.

Side Effects and Monitoring After Starting

The most common adverse effects of dulaglutide are gastrointestinal: nausea (12.4% vs. 5.3% placebo), diarrhea (8.9% vs. 6.0%), vomiting (6.0% vs. 2.3%), and abdominal pain (6.5% vs. 4.0%), based on pooled phase 3 data in the FDA label [1]. These effects are typically dose-dependent and diminish after the first 4 to 8 weeks.

Prescribers in Alaska should monitor:

• HbA1c at 3 months after initiation and every 3 to 6 months thereafter, per ADA 2024 recommendations [5].
• Body weight. Dulaglutide produces modest weight reduction; AWARD-11 (N=1,842) showed 4.5 mg weekly produced 4.7 kg mean weight loss at 36 weeks versus 2.7 kg with 1.5 mg [15].
• Heart rate. GLP-1 receptor agonists can increase resting heart rate by 2 to 4 bpm. Monitoring is warranted in patients with tachyarrhythmia history.
• Pancreatitis symptoms. Patients should be counseled to report severe, persistent abdominal pain and to discontinue dulaglutide pending evaluation [1].
• Injection site reactions. Usually mild; rotation of injection sites minimizes the risk.

A 2021 meta-analysis in JAMA Cardiology (27 trials, N=87,162) confirmed that GLP-1 receptor agonists as a class reduce cardiovascular mortality (RR 0.88 to 95% CI 0.82, 0.94) and all-cause mortality (RR 0.89 to 95% CI 0.84, 0.94) compared with placebo [16].